

Orthospec Study Synopsis


"The bottom line"

During the clinical trial of the Orthospec, 196 patients were screened and 172 randomized to either the Orthospec treatment or Placebo. 168 patients were included in the final analysis. The main goal of the study was to assess the improvement of patients' heel pain measured by the Visual Analog Scale (pain score).

The outcome of the study demonstrated a significant difference between the Orthospec treatment and the Placebo treatment in the improvement of pain.

- **Response Rate at Month 3:** In terms of the decrease in patients' pain levels, from baseline to 3 months in both the investigators' assessment of heel pain and the patients assessment of heel pain –
 - **72%** of Orthospec patients (vs. 54% in placebo group) showed a decrease in pain level (VAS pain scale) of 3 cm or more
 - **86%** of patients (vs. 69% in placebo group) showed a decrease in pain level (VAS pain scale of) 1 or more
 - **65%** of patients demonstrated success in the investigator's heel pain assessment (as defined in the study protocol)

Change From Baseline to Month 3 in Best Response between Investigator and Subject VAS Orthospec Patients with Level > 4.5



Note: At enrollment, eligible patients had VAS scores of ≥ 5 cm on VAS pain scale. Physicians find that an improvement in pain of 2 to 3 cm is highly significant.